Robert Barski

Mr. Robert Barski

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2013 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
PDF file
DNDeepa Narayanan
Deepa Narayanan
RBRobert Barski
Robert Barski
MHMick J Henderson
Mick J Henderson
ALAhai Luvai
Ahai Luvai
DCDeepak Chandrajay
Deepak Chandrajay
RSReena Sharma
Reena Sharma
Phenylketonuria (PKU), is an autosomal recessive condition affecting the amino acid metabolism. The UK National newborn screening programme was commenced in 1969 and PKU is one among the five conditions included in the screening programme. We present the case history of two siblings of a family with a delayed diagnosis of PKU. This case history highlights such an occurrence. PKU should be considered as an important differential in the diagnosis of adult patients with learning difficulties, seizures and behavioural problems. It would be prudent to instigate plasma and urine amino/organic acid analyses in adult patients with unexplained neuropsychological manifestations.

Verified
Journal Article
Open access
PDF file
NCNathan William Patrick Cantley
Nathan William Patrick Cantley
RBRobert Barski
Robert Barski
HKHelena Kemp
Helena Kemp
SHSarah L Hogg
Sarah L Hogg
HWHoi Yee Wu
Hoi Yee Wu
SMStuart Moat
Stuart Moat
In the UK, Classical Galactosaemia (CG) is identified incidentally from the Newborn Screening (NBS) for phenylketonuria (PKU) using an “Other disorder suspected” (ODS) pathway when phenylalanine (Phe) and tyrosine (Tyr) concentrations are increased. We aimed to determine the efficacy of CG detection via NBS and estimate the incidence of CG in live births in the UK. A survey was sent to all UK NBS laboratories to collate CG cases diagnosed in the UK from 2010 to 2020. Cases of CG diagnosed were determined if detected clinically, NBS, or by family screening, as well as age at diagnosis. Cases referred via the ODS pathway were also collated, including the final diagnosis made. Responses were obtained from 13/16 laboratories. Between 2010 and 2020, a total of 6,642,787 babies were screened, and 172 cases of CG were identified. It should be noted that 85/172 presented clinically, 52/172 were identified by NBS, and 17/172 came from family screening. A total of 117 referrals were made via the ODS pathway, and 45/117 were subsequently diagnosed with CG. Median (interquartile range) age at diagnosis by NBS and clinically was 8 days (7–11) and 10 days (7–16), respectively (Mann–Whitney U test, U = 836.5, p-value = 0.082). The incidence of CG is 1:38,621 live births. The incidence of CG in the UK is comparable with that of other European/western countries. No statistical difference was seen in the timing of diagnosis between NBS and clinical presentation based on the current practice of sampling on day 5. Bringing forward the day of NBS sampling to day 3 would increase the proportion diagnosed with CG by NBS from 52/172 (30.2%) to 66/172 (38.4%).

10 February 2023 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
SHSarah L Hogg
Sarah L Hogg
RCRachel Carling
Rachel Carling
NCNathan Wp Cantley
Nathan Wp Cantley
GHGillian Hamilton
Gillian Hamilton
PGPhilippa Goddard
Philippa Goddard
HKHelena J Kemp
Helena J Kemp
Background: Sapropterin has been approved as a treatment option for individuals with Phenylketonuria in the United Kingdom. Individuals are assessed as responsive to Sapropterin by a ≥30% reduction in Phenylalanine (Phe) concentrations using dried blood spot (DBS) specimens. DBS quality is critical for accurate and precise measurement of Phe. Currently, UK national guidelines for DBS specimen acceptance do not exist for patient-collected DBS specimens. We adopted evidence-based guidelines for specimen acceptance criteria and retrospectively assessed the impact of introducing these guidelines on specimen rejection rates. Methods: Laboratories were invited to audit the quality of DBS specimens routinely received for Phe monitoring using: (1) existing acceptance/rejection criteria and (2) proposed national guidelines. Results: Ten laboratories audited 2111 specimens from 1094 individuals. Using existing local guidelines, the median rejection rate was 4.0% (IQR 1.5–7.2%). This increased to 21.9% (IQR 10.0–33.0%) using the proposed guidelines. Where reason(s) for rejection were provided ( n = 299); 211/299 (70.6%) of DBS specimens were too small or multi-spotted. 380 individuals had more than one sample evaluated; 231/380 (60.8%) provided specimens of acceptable quality, 37/380 (9.7%) consistently provided poor-quality DBS specimens. Conclusions: There is significant variability in the quality of patient-collected DBS specimens. If unacceptable specimens are not rejected, imprecise/inaccurate results will be used in clinical decision making. Using annual workload data for England, this equates to 12,410 incorrect results. Individuals and parents/carers should receive ongoing training in blood collection technique to ensure use of evidence-based acceptability criteria does not cause undue distress from increased sample rejection rates.

Verified
Journal Article
Open access
PDF file
RCRachel Carling
Rachel Carling
ZBZoe J. Barclay
Zoe J. Barclay
SWSophie C Ward
Sophie C Ward
MAMarie Appleton
Marie Appleton
RBRobert Barski
Robert Barski
James BonhamJames Bonham
James Bonham
Newborn screening in England is a national program with laboratories adhering to common screening algorithms. Until recently, screening for inherited metabolic disorders was provided by ten laboratories using laboratory-developed tests (LDTs) and three using commercial assays: harmonization of results proved challenging. Introduction of hereditary tyrosinemia type 1 screening meant LDTs required modification to include the measurement of succinylacetone, and subsequent re-validation. This provided an opportunity to implement a single commercial reagent kit in all laboratories. It was anticipated that this would improve analytical performance and harmonization. This study aimed to determine whether these goals were achieved. Verification across the 13 laboratories revealed that the commercial kit reduced inter-laboratory variation for all analytes demonstrating improved harmonization. However, this was achieved by applying instrument-specific correction factors to all analytes, the magnitude of which were significant, indicating a lack of standardization. Performance of succinylacetone was limited by instrument-dependent background interference from the methionine stable isotope label, underscoring the need to establish evidence-based screening cut-off values (COV) rather than adopting published thresholds. This study emphasizes the need for traceable reference materials to improve laboratory quality and the value of screening outcome data.

14 August 2025 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
RBRoger Bramley
Roger Bramley
DHDaniel Herrera
Daniel Herrera
RBRobert Barski
Robert Barski
MHMichael Henderson
Michael Henderson
Fourier-transformed infrared (FTIR) spectroscopy is a frequently requested test in patients with kidney stones. It is considered particularly useful when routine stone urine screens do not identify any significant abnormalities. This case report describes a patient with undiagnosed adenine phosphoribosyltransferase (APRT) deficiency, a disorder presenting with kidney stones, who had initial symptoms at 16 months of age but no diagnosis until they were 6 years old. Initial investigations including a urine stone screen did not show significant abnormalities; however, FTIR analysis suggested the stones had a significant component identified as lansoprazole, a drug the patient was not taking. After repeated stone formation, urinary tract infections and inpatient stays, the disorder was identified incidentally during validation of a method for purine and pyrimidines in urine. This case highlights that FTIR analysis, although useful, has pitfalls and that other investigations are of equal value in reaching a diagnosis.

2 October 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
BBBevin Bhoyrul
Bevin Bhoyrul
DWDavid Wright
David Wright
LHLesley Heptinstall
Lesley Heptinstall
RBRobert Barski
Robert Barski
IBIan Berry
Ian Berry
SCSheila Clark
Sheila Clark